A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.82-0.37 (-0.82%)
NVS$53.13-0.16 (-0.3%)
SNY$37.67-0.01 (-0.03%)
GSK$41.530.06 (0.14%)
click here
Conference Coverage

More Evidence that Vitamin D Reduces Risk of Cancer in Women

Researchers from Harvard have shown that higher intakes of calcium and vitamin D may reduce the risk of developing premenopausal breast cancer.[1] The details of this study appeared in the May 28, 2007 issue of the Archives of Internal Medicine. In a separate report published in the June 2007 issue of TheAmerican Journal of Clinical Nutrition, researchers from Creighton University reported that supplementation with vitamin D and calcium reduces the risk of cancer.[2]  

There is increasing evidence that higher intakes or increased levels of vitamin D are associated with a decreased risk of several types of cancer. The current data suggests that doses of 1-2000 IU/day are necessary for this preventative effect.  

The Harvard study evaluated total calcium and vitamin D intake in over 10,000 premenopausal and 20,000 postmenopausal women who were free of cancer at the beginning of the study. The average duration of study was 10 years. These authors reported that the risk of developing premenopausal breast cancer was 40% less in women with the highest compared to the lowest intake of vitamin D. They also reported a lower incidence of large and aggressive cancers in women with the highest intake of vitamin D and calcium. This relationship was not observed in post-menopausal women.  

The study from Creighton University randomly allocated 1,179 women >55 years of age to receive 1400-1500 mg of calcium, the same dose of calcium plus 1100 IU/day of vitamin D3 or placebo. They reported that after the first 12 months, the risk of developing any cancer fell by 77% for the calcium plus vitamin D group but not for the calcium alone group compared to placebo. These researchers concluded that the risk of cancer was significantly reduced by vitamin D and calcium supplementation.  

Comments: The data from Harvard is consistent with a previous study from the Women’s Health Initiative presented at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO) where calcium plus vitamin D supplements did not reduce the risk of breast cancer in postmenopausal women. The observation that vitamin D can reduce the risk of developing premenopausal breast cancer is of major interest. The Creighton University study is one of the few randomized trials to show an effect of vitamin D supplementation on reducing the risk of cancer.  

References:

[1] Lin J, Manson JE, Lee I-M, et al. Intakes of calcium and vitamin D and breast cancer risk in women. Archives of Internal Medicine. 2007; 167:1050-1059.

[2] Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. The American Journalof Clinical Nutrition. 2007; 85:1586-1591.  

Related News:  

1-2000 IU/Day of Vitamin D Recommended for Prevention of Colorectal Cancer (03/09/2007)

Increased Vitamin D Intake Reduces Risk of Pancreatic Cancer (09/20/2006)

Breast Cancer Risk Not Reduced by Calcium Plus Vitamin D (06/13/2006)

Role of Vitamin D in Breast Cancer Prevention Explored at 97th AACR Meeting (05/02/2006)

Higher Levels of Vitamin D May Protect Against Cancer in Men (04/07/2006)

Calcium and Vitamin D Supplementation May Not Prevent Colorectal Cancer (03/06/2006)

Reports Emphasize Importance of Relatively Large Doses of Vitamin D for Cancer Prevention (01/09/2006)





 

Newsletters
Register in our member center today to receive a monthly newsletter with conference coverage updates.
Learn More »
Practice Resources
Learn how to have our conference coverage on your website.
Learn More »
Related News Stories
Maintenance Rituxan® Is Safe for Follicular Lymphoma (7/8/2008)

Gemcitabine, Rituximab, Oxaliplatin, and Pegfilgrastim Active for Relapsed NHL (6/27/2008)

Lumiliximab and FCR Promising for Relapsed CLL (6/26/2008)

Flavopiridol Has Significant Activity in Relapsed Chronic Lymphocytic Leukemia (6/25/2008)

Sprycel® Effective for Patients with Newly Diagnosed CML (6/24/2008)

Tasigna® Effective for Patients with Newly Diagnosed CML (6/24/2008)

Patients with KRAS Mutation Do Not Benefit from EGFR Inhibitors (6/20/2008)

Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer (6/20/2008)

Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure? (6/19/2008)

Radiation Therapy for Prostate Cancer Increases Incidence of AML (6/18/2008)

Quinamed® + ARA-C Effective for Secondary Acute Myeloid Leukemia (6/17/2008)

Statins May Reduce Acute Graft-versus-host Disease (6/17/2008)

Provigil®, a Eugeroic Agent, Improves Severe Cancer-related Fatigue (6/13/2008)

Results of Treating NHL Patients over the Age of 80 Reported at ASCO (6/12/2008)

Single-dose Carboplatin Confirmed as Effective as Radiation Therapy for Stage I Seminoma (6/12/2008)

Dose-dense Chemotherapy Effective for Localized Ewing’s Sarcoma (6/11/2008)

Mayo Clinic Reports Increasing Use of Mastectomy for Early-stage Breast Cancer (6/11/2008)

Brachytherapy May Be Treatment of Choice for Endometrial Cancer (6/10/2008)

Gemzar® Improves Survival in Early Pancreatic Cancer (6/9/2008)

Addition of Tykerb® to Herceptin® Improves Time to Progression in Herceptin Pre-treated Breast Cancer (6/6/2008)

Addition of Avastin® to Taxotere® Improves Progression-free Survival in Advanced HER2-negative Breast Cancer (6/6/2008)

Nexavar® Delays Progression of Heavily Pre-treated NSCLC (6/6/2008)

Acupuncture Reduces Pain after Neck Dissection (6/6/2008)

VePesid®/Platinol® Remains Standard of Care for Small Cell Lung Cancer (6/6/2008)

Blood Test Shows Promise for Early Detection of Lung Cancer (6/6/2008)

Tykerb® Monotherapy Active in HER2-positive Refractory Inflammatory Breast Cancer (6/6/2008)

CDX-110 Vaccine May Improve Survival in Brain Cancer (6/5/2008)

Sites of Relapse in Breast Cancer May Require Biopsy to Accurately Determine HER2 or Hormone Status (6/5/2008)

Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Renal Cell Cancer (6/4/2008)

Conventional Chemotherapy Outperforms Xeloda® in Older Breast Cancer Patients (6/4/2008)




© 1998-2007 CancerConsultants.com  All Rights Reserved.